Phagenix

Phagenesis is a medical technology company that has developed a novel treatment for dysphagia, a condition characterized by difficulty swallowing often following a stroke or critical illness. The company's flagship product, the Phagenyx system, utilizes Pharyngeal Electrical Stimulation (PES) to restore neurological control of swallowing by stimulating the sensory nerves in the throat. This therapy is designed to accelerate the recovery of swallowing function, thereby reducing complications such as aspiration pneumonia and shortening hospital stays. Headquartered in the United Kingdom, Phagenesis was acquired by Nestlé Health Science to expand its portfolio of nutritional and therapeutic solutions for gastrointestinal and neurological health.